China approved 48 first-in-class innovative drugs, as well as a significant number of medications for pediatric and rare diseases, thanks to measures aimed at enhancing review efficiency and accelerating patient access to novel therapies, according to a report released by China’s National Medical Products Administration.
The extent of the damage that will be caused if the U.S. overseas aid program, the President’s Emergency Plan for AIDS Relief (PEPFAR), is axed or has its funding cut, is laid out in an expert analysis published in The Lancet April 8, which estimates nearly 500,000 children could die from AIDS-related causes by 2030, while 1 million children will be infected with the virus.
New vaccines to control tuberculosis (TB) are urgently needed to fight the global burden of the disease, the increase of resistant strains and the lack of effective vaccines to prevent latent TB infections.
Compared to other forms of prevention, a unique issue for pandemic preparedness is that it is forever unclear what pathogen, exactly, the world needs to be prepared for. There are an estimated 300,000 viruses that infect mammals; add in birds, and the estimate grows to more than half a million. Some of those viruses are much greater threats than others.
China approved 48 first-in-class innovative drugs, as well as a significant number of medications for pediatric and rare diseases, thanks to measures aimed at enhancing review efficiency and accelerating patient access to novel therapies, according to a report released by China’s National Medical Products Administration.
National Science & Technology Development Agency (NSTDA) has described cordycepin derivatives acting as viral replication inhibitors reported to be useful for the treatment of viral infections.
Using its proprietary FBDD platform, Blacksmith discovered FG-2101, the prodrug form of FG-960, the first known non-hydroxamate LpxC inhibitor that exerted activity against LpxC at the nanomolar range.
Biomedical research seems like it should be the ultimate bipartisan issue. But under the Trump administration, unless and until Congress regains its will to make use of its constitutional powers, bipartisan support for research seems to be a thing of the past.
Amenis Bioscience Inc. has identified anthranilic acid derivatives acting as peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 (PIN1) and viral replication inhibitors reported to be useful for the treatment of parasitic and viral infections, obesity, cancer, nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH), inflammatory bowel disease and pulmonary fibrosis.
RSS
